RESUMEN
It has been previously shown that dextran sulfate administered to diabetic rats accumulates in the liver and kidney, and this could be due to a malfunction of the lysosomal digestive pathway. The aim of the present study was to evaluate the expression and activities of lysosomal enzymes that act upon proteins and sulfated polysaccharides in the livers of diabetic rats. Diabetes mellitus was induced by streptozotocin in 26 male Wistar rats (12 weeks old), while 26 age-matched controls received only vehicle. The livers were removed on either the 10th or the 30th day of the disease, weighed, and used to evaluate the activity, expression, and localization of lysosomal enzymes. A 50-60% decrease in the specific activities of cysteine proteases, especially cathepsin B, was observed in streptozotocin-induced diabetes mellitus. Expression (mRNA) of cathepsins B and L was also decreased on the 10th, but not on the 30th day. Sulfatase decreased 30% on the 30th day, while glycosidases did not vary (or presented a transitory and slight decrease). There were no apparent changes in liver morphology, and immunohistochemistry revealed the presence of cathepsin B in hepatocyte granules. The decrease in sulfatase could be responsible for the dextran sulfate build-up in the diabetic liver, since the action of sulfatase precedes glycosidases in the digestive pathway of sulfated polysaccharides. Our findings suggest that the decreased activities of cathepsins resulted from decreased expression of their genes, and not from general lysosomal failure, because the levels of glycosidases were normal in the diabetic liver.
Asunto(s)
Animales , Masculino , Catepsina B/metabolismo , Diabetes Mellitus Experimental/enzimología , Hígado/enzimología , Lisosomas/enzimología , Albúminas/análisis , Western Blotting , Glucemia/efectos de los fármacos , Catepsina L/metabolismo , Creatinina/orina , Proteasas de Cisteína/metabolismo , Sulfato de Dextran/farmacología , Diabetes Mellitus Experimental/inducido químicamente , Expresión Génica/efectos de los fármacos , Glucuronidasa/metabolismo , Hexosaminidasas/metabolismo , Inmunohistoquímica , Riñón/metabolismo , Ratas Wistar , Reacción en Cadena en Tiempo Real de la Polimerasa , ARN , Sulfatasas/metabolismoAsunto(s)
Toxicología , Toxicología , Venenos , Intoxicación , Toxinas Biológicas , Toxicología , BioquímicaAsunto(s)
Biodiversidad , Bioquímica , Farmacología , Alergia e Inmunología , Zoología , BiodiversidadAsunto(s)
Toxicología , Toxicología , Venenos , Intoxicación , Toxinas Biológicas , Toxicología , BioquímicaAsunto(s)
Toxicología , Toxicología , Venenos , Intoxicación , Toxinas Biológicas , Toxicología , Bioquímica , Biotecnología , GenéticaAsunto(s)
Toxicología , Toxicología , Venenos , Intoxicación , Toxinas Biológicas , Toxicología , BioquímicaRESUMEN
Background and purpose: S100A9 protein induces anti-nociception in rodents, in different experimental models of inflammatory pain. Herein, we investigated the effects of a fragment of the C-terminus of S100A9 (mS100A9p), on the hyperalgesia induced by serine proteases, through the activation of protease-activated receptor-2 (PAR2). Experimental approach: Mechanical and thermal hyperalgesia induced by PAR2 agonists (SLIGRL-NH2 and trypsin) was measured in rats submitted to the paw pressure or plantar tests, and Egr-1 expression was determined by immunohistochemistry in rat spinal cord dorsal horn. Calcium flux in human embryonic kidney cells (HEK), which naturally express PAR2, in Kirsten virus-transformed kidney cells, transfected (KNRK-PAR2) or not (KNRK) with PAR2, and in mouse dorsal root ganglia neurons (DRG) was measured by fluorimetric methods. Key results: mS100A9p inhibited mechanical hyperalgesia induced by trypsin, without modifying its enzymatic activity. Mechanical and thermal hyperalgesia induced by SLIGRL-NH2 were inhibited by mS100A9p. SLIGRL-NH2 enhanced Egr-1 expression, a marker of nociceptor activation, and this effect was inhibited by concomitant treatment with mS100A9p. mS100A9p inhibited calcium mobilization in DRG neurons in response to the PAR2 agonists trypsin and SLIGRL-NH2, but also in response to capsaicin and bradykinin, suggesting a direct effect of mS100A9 on sensory neurons. No effect on the calcium flux induced by trypsin or SLIGRL in HEK cells or KNRK-PAR2 cells was observed. Conclusions and implications: These data demonstrate that mS100A9p interferes with mechanisms involved in nociception and hyperalgesia and modulates, possibly directly on sensory neurons, the PAR2-induced nociceptive signal.